Crawford Strunk, MD

I am a member of the American Society of Hematology, where I serve on the Steering Committee of the Sickle Cell Disease Coalition. I am on the Board of Directors of the National Alliance of Sickle Cell Centers, the executive team of the Sickle Cell Adult Provider Network, and I am also the Vice Chief Medical Officer of the Sickle Cell Disease Association of America.

See publications for this provider. (Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Cleveland Clinic physicians and scientists collaborate with industry to advance medical breakthroughs. These partnerships help commercialize discoveries for public benefit while maintaining scientific integrity. To ensure transparency and minimize potential bias, Cleveland Clinic reviews these relationships and publicly discloses when physicians/scientists receive significant compensation for consulting, serve in fiduciary roles, receive royalties, or hold equity interests related to their work. We manage potential conflicts through approval processes, annual reporting, and targeted management plans.

As of 2026-03-20, Dr. Strunk has reported the financial relationships with the companies listed below.

Consulting and/or Speaking. Dr. Strunk receives fees of $5,000 or more per year (or, in rare cases, equity or stock options) as a paid consultant, speaker or as a member of an advisory committee for the following companies:

• Pfizer, Inc.

Fiduciary Role. Dr. Strunk serves in a fiduciary capacity, such as an elected officer, director or chief medical officer, for the following companies or other entities:

• Scott Center for Observation Treatment and Transition
• Sickle Cell Disease Association of America, Inc.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.